RADX Overview

Market Performance: The stock market experienced moderate gains due to softer inflation data and stable unemployment, with the Dow Jones and S&P 500 rising, while the Nasdaq rebounded, indicating investor confidence in a potential rate cut by the Federal Reserve in 2026.

Earnings Highlights: Micron Technology exceeded expectations and raised its guidance, boosting AI-related semiconductor stocks, while Nike's cautious outlook on global demand, especially in China, led to a decline in its shares.

Sector Resilience: Transportation and travel sectors showed strength, with FedEx reporting solid quarterly results and Carnival Corporation reinstating its dividend and forecasting strong demand for 2026, despite ongoing macroeconomic uncertainties.

Investor Sentiment: Reports indicated a shift in focus from hype around AI to companies demonstrating clear profitability, with notable bearish sentiments surrounding stocks like Meta and Novo Nordisk, which faced challenges in their respective markets.

U.S. Stock Market Performance: U.S. stocks traded mostly lower, with the Dow Jones falling over 50 points, while the S&P 500 and NASDAQ also experienced slight declines. Information technology shares rose by 0.1%, but energy stocks dropped by 1.8%.

Job Market Update: The U.S. economy added 64,000 jobs in November, slightly above expectations but still below healthy job creation levels. The unemployment rate rose to 4.6%, marking the highest since September 2021.

Equities Trading Highlights: SRx Health Solutions saw a significant increase in shares by 117% after an acquisition announcement, while Zynex Inc shares plummeted 59% due to entering Chapter 11 restructuring.

Global Market Trends: European and Asian markets closed lower, with notable declines in major indices like Japan's Nikkei and Spain's IBEX 35. In commodities, oil prices fell by 1.9%, while gold saw a slight increase.

B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.

Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.

Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.

Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.

Stock Performance: Radiopharm Theranostics Limited (NASDAQ: RADX) saw its stock rise 141.31% to $10.27 on Monday, with a trading volume significantly higher than its average.

Clinical Trial Results: The company shared promising interim data from its Phase 2b trial of RAD 101, showing that 92% of patients achieved concordance with MRI in detecting brain metastases.

Market Potential: RAD 101 is projected to have a U.S. market opportunity exceeding $500 million annually, with the company aiming to initiate a pivotal study by the end of 2026.

Regulatory Milestones: RAD 101 has received FDA Fast Track Designation, and the company has also secured approval for a Phase 1 trial of RAD 402 for treating advanced prostate cancer.

RAD 402 Overview: RAD 402 is a humanized IgG1 monoclonal antibody targeting KLK3, designed for the treatment of metastatic or locally advanced prostate cancer, and has received HREC approval for its first-in-human Phase 1 clinical trial in Australia.

Mechanism of Action: The treatment utilizes the radionuclide 161Tb, which emits both beta particles and Auger electrons, showing promising antitumor activity based on preclinical studies that demonstrated effective tumor targeting and minimal side effects.

Company Background: Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals, with a diverse pipeline that includes multiple Phase 1 and Phase 2 trials across various solid tumor cancers.

Regulatory Milestone: The approval from the Bellberry HREC is a significant milestone for Radiopharm, allowing the advancement of RAD 402 into clinical trials and highlighting the potential for new, safer treatments for prostate cancer patients.